It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X-Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X-Y sequences may be the same or different.

Claims

15 · 1 independent · depth 3

15 granted claims

›1.independentA method for targeting a labeled probe and/or drug to a tumor site, which comprises administering to a living body, a hydrophilic polymer-modified car…+14

›2.↳ 1The method according to claim 1, wherein the hydrophilic polymer-modified carrier is a liposome containing a lipid membrane component modified with a …d2

›3.↳ 1The method according to claim 1, wherein the molecular weight of the gelatin-like protein is 2 KDa to 100 KDa.d2

›4.↳ 1The method according to claim 1, wherein the gelatin-like protein is represented by the formula:nA-[(Gly-X-Y)n]m-Bd2

›5.↳ 1The method according to claim 1, wherein the gelatin-like protein is represented by the formula:nGly-Ala-Pro-[(Gly-X-Y)63]3-Glyd2

›6.↳ 1The method according to claim 1, wherein the cell adhesion signal is an amino acid sequence represented by Arg-Gly-Asp.d2

›7.↳ 1The method according to claim 1, wherein the amino acid sequence of the gelatin-like protein does not comprise any of serine and threonine.d2

›8.↳ 1The method according to claim 1, wherein the amino acid sequence of the gelatin-like protein does not comprise any of serine, threonine, asparagine, t…d2

›9.↳ 1The method according to claim 1, wherein the amino acid sequence of the gelatin-like protein does not comprise an amino acid sequence represented by A…d2

›10.↳ 1The method according to claim 1, wherein the gelatin-like protein has (1) the amino acid sequence shown in SEQ ID NO: 1, or (2) an amino acid sequence…d2

›11.↳ 1The method according to claim 1, wherein the gelatin-like protein is crosslinked.d2

›12.↳ 1The method according to claim 1, wherein the crosslinking is carried out using an aldehyde, a condensing agent or an enzyme.d2

›13.↳ 1The method according to claim 1, wherein the hydrophilic polymer is polyethylene glycol.d2

›14.↳ 1The method according to claim 1, wherein the labeled probe is a fluorescent dye, a radioisotope, a nuclide used for PET, a nuclide used for SPECT, an …d2+1

Classifications

4 codes

IPC · International Patent Classification

Section A — Human necessities

A61K49/00
A61K51/08

USPC · US Patent Classification

424/1.69514/17.2

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.0 y

1,453 days filing → grant

Office actions

non-final + final

Responses

no RCE

Examiner

Karlheinz R Skowronek

art unit 1676 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 41 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20130017147 A1	17 Jan 2013

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.